Surender Kharbanda - 11 Jan 2022 Form 3 Insider Report for Hillstream BioPharma Inc. (THAR)

Reporting relationship
10%+ Owner
Issuer ticker
THAR
Reported as of
11 Jan 2022
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
11 Jan 2022, 20:53:52 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Surender Kharbanda

Key filing fact

Surender Kharbanda filed Form 3 for Hillstream BioPharma Inc. (THAR) on 11 Jan 2022.

Key facts

  • This page summarizes Surender Kharbanda's Form 3 filing for Hillstream BioPharma Inc. (THAR).
  • 0 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 11 Jan 2022, 20:53.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HILS holding

Common stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
721,240
Date
11 Jan 2022
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HILS holding Derivative

Options (right to purchase)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
11 Jan 2022
Ownership
Direct
Underlying class
Common stock
Underlying amount
946
Exercise price
$7.82
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Registrant issued the Reporting Person the options on January 1, 2021. The options vested and became exercisable immediately upon grant.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .